Filing Flows › Citius Oncology (CTOR) › Who owns the stock
Who owns Citius Oncology (CTOR) stock
18 funds reported Citius Oncology (CTOR) shares in their latest 13F filings, worth $9.7M in all. The largest holder is Armistice Capital, LLC ($5.7M). Last quarter 9 funds added to their stakes and 5 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Armistice Capital, LLC | 8,705,589 | $5.7M | decrease | 2026-06-30 |
| Bank of America | 3,835,160 | $2.5M | unchanged | 2026-06-30 |
| Vanguard Group | 596,997 | $597K | increase | 2025-12-31 |
| Vanguard Capital Management LLC | 546,325 | $355K | increase | 2026-06-30 |
| UBS Group AG | 334,619 | $218K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 245,407 | $160K | decrease | 2026-06-30 |
| Vanguard Fiduciary Trust | 121,910 | $79K | unchanged | 2026-06-30 |
| Citadel Advisors LLC | 90,586 | $59K | new | 2026-06-30 |
| Northern Trust | 45,746 | $30K | unchanged | 2026-06-30 |
| State Street | 42,900 | $28K | unchanged | 2026-06-30 |
| Virtu Financial LLC | 21,877 | $14K | new | 2026-06-30 |
| XTX Topco | 20,638 | $13K | new | 2026-06-30 |
| StoneX Group | 13,719 | $12K | new | 2026-09-30 |
| Tower Research Capital LLC | 13,816 | $9K | new | 2026-06-30 |
| Arkadios Wealth Advisors | 11,666 | $8K | unchanged | 2026-06-30 |
Citius Oncology's latest quarter
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most CTOR stock?
By the latest 13F filings: Armistice Capital, LLC ($5.7M); Bank of America ($2.5M); Vanguard Group ($597K); Vanguard Capital Management LLC ($355K); UBS Group AG ($218K).
What is the short interest in CTOR?
227,455 shares were sold short at the 2026-10-15 settlement, -21.49% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.